Product
BT5528
Name
BT5528
1 clinical trial
7 indications
Indication
Bladder CancerIndication
Ovarian CancerIndication
Lung CancerIndication
Head and Neck CancerIndication
Triple-Negative Breast CancerIndication
Gastric CancerClinical trial
Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients With Advanced Malignancies Associated With EphA2 ExpressionStatus: Recruiting, Estimated PCD: 2023-12-31